Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 9/11/2018
SIETES contiene 92577 citas

 
 
 1 a 20 de 1318 siguiente >>
Presentar resultados
Seleccionar todas
2.Enlace a cita original Cita con resumen
Cortese A, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018:7 de agosto. [Ref.ID 102788]
3.Enlace a cita original Cita con resumen
Hales CM, Kit BK, Gu Q, Ogden CL. Trends in prescription medication use among children and adolescents—United States, 1999-2014. JAMA 2018;319:15 de mayo. [Ref.ID 102778]
5. Cita con resumen
Anónimo. Study shows that nearly half of overdose deaths are from fentanyl. DIA Daily 2018:3. [Ref.ID 102704]
6.Enlace a cita original Cita con resumen
Salm-Reifferscheidt L. Tramadol: Africa's opioid crisis. Lancet 2018;391:19 de mayo. [Ref.ID 102613]
7. Cita con resumen
Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants — United States, 2015–2016. Morbidity and Mortality Weekly Report 2018;67:30 de marzo. [Ref.ID 102488]
8.Enlace a cita original Cita con resumen
Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K, Gissler M, Hernández-Díaz S, Karlsson P, Karlstad Ø, Kieler H, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Sørensen HT, Zoega H, Bateman BT. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry 2017:13 de diciembre. [Ref.ID 102188]
9. Cita con resumen
Anónimo. Guanfacine et déficit de l'attention avec hyperactivité. Prescrire 2017;37:329-32. [Ref.ID 101647]
10. Cita con resumen
Anónimo. Pitolisant et narcolepsie. Prescrire 2017;37:333-5. [Ref.ID 101643]
12. Cita con resumen
Chanq Z, Quinn PD, Hur K, Gibbons RD, Sjolander A, Larsson H, D'Onofrio BM. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 2017;74:597-603. [Ref.ID 101569]
13. Cita con resumen
Anónimo. Pitolisant for narcolepsy. Drug Ther Bull 2017;55:6-8. [Ref.ID 101353]
14. Cita con resumen
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424-34. [Ref.ID 100458]
15.Enlace a cita original Cita con resumen
Hoshen MB, Benis A, Keyes KM, Zoëga H. Stimulant use for ADHD and relative age in class among children in Israel. Pharmacoepidemiol Drug Saf 2016;25:652-60. [Ref.ID 100395]
16. Cita con resumen
Jackson JW. The cardiovascular safety of methylphenidate. BMJ 2016;353:i2874. [Ref.ID 100356]
18. Cita con resumen
20. Cita con resumen
Anonimo. FDA approves chewable version of AD/HD stimulant medication. DIA Daily 2015:1. [Ref.ID 99726]
Seleccionar todas
 
 1 a 20 de 1318 siguiente >>